Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.
Outcomes included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), overall survival (OS), progression-free survival (PFS), relapse incidence (RI), and non-relapse mortality (NRM).